AFP and neoplasm: Currently, the clinical management of advanced TGCT disease is based on classical serum protein markers (alpha‐fetoprotein [AFP], β‐human chorionic gonadotropin [HCG], and lactate dehydrogenase [LDH]), and imaging studies.7, 8 However, only 60% of TGCTs demonstrate elevated serum tumour markers at initial diagnosis.